The main goal of this study was to assess potential differential associations of treatment by CHEK2 c.1100delC status with CBC risk and to investigate if the poorer survival in CHEK2 c.1100delC carriers may be explained alone by the occurrence of CBC. This evidence concerns the gene CHEK2 and complete blood cell count.